Vertaling van "forward productivity " (Nederlands → Frans) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat barbituraat bevat
produit contenant du barbiturique

product dat baricitinib bevat
produit contenant du baricitinib

IN-CONTEXT TRANSLATIONS

Forward productivity program exceeds savings goal by nearly 50% and a year ahead of schedule
Le programme de productivité Forward dépasse son objectif d’économies de près de 50% avec un an d’avance

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Consumer Health continuing operations: +124% to USD 190 million Excluding USD 97 million of Forward restructuring charges in 2007, operating income rose 4% mainly on strong underlying growth in CIBA Vision and productivity gains across the businesses, but was impacted by negative currency movements.
Consumer Health, activités poursuivies: +124% à USD 190 millions Hors charges de restructuration Forward d'USD 97 millions en 2007, le résultat opérationnel a progressé de 4%, essentiellement en raison d’une forte croissance sousjacente de CIBA Vision et de gains de productivité dans toutes les activités, mais il a subi l'effet de taux de change défavorables.

Consumer Health continuing operations: +29% to USD 1.0 billion Robust growth in operating income outpaced net sales thanks to the business expansion, particularly in CIBA Vision, and Forward-related productivity gains.
Consumer Health, activités poursuivies: +29% à USD 1,0 milliard La croissance robuste du résultat opérationnel a surpassé celle du chiffre d’affaires net grâce à l’expansion des activités, en particulier à CIBA Vision, et à des gains de productivité liés à Forward.

Operating income advanced 32% to USD 9.0 billion due to the solid business expansion as well as productivity gains from Forward, the Group’s efficiency initiative that is freeing up resources for investments in innovation and expansion in high-growth markets.
Le résultat opérationnel a progressé de 32% à USD 9,0 milliards grâce à la solide expansion des activités et à des gains de productivité dégagés par Forward, le projet visant à accroître l’efficience du Groupe.

Operating cash flow in the first half of 2008 also included restructuring payments for the Forward productivity initiative.
Les flux de trésorerie opérationnels du premier semestre de l’exercice précédent ont également compris des paiements de restructuration pour le projet Forward destiné à accroître la productivité.

Forward, an initiative for greater productivity, increased efficiency and speed, is progressing rapidly ahead of schedule with USD 631 million of incremental savings in the first half of 2009, which are being partially reinvested to bolster growth.
Forward, un projet destiné à accroître la productivité, l’efficience et la rapidité, progresse rapidement en avance sur le plan. Il a permis de réaliser de manière progressive et continue USD 631 millions d’économies au premier semestre 2009.